



## PATHOPHYSIOLOGY OF ENDOCRINE AND METABOLIC DISORDERS AMONG PATIENTS WITH POLY CYSTIC OVARIAN SYNDROME

**Sneha Jaiswal\***

Senior Resident, Department of Physiology, Bowring and lady Curzon Medical college and research institute, Bangalore Karnataka  
\*Corresponding author

**Ranjit Kumar**

Senior Resident, Department of Pediatrics, NMCH, Patna.

**Srinivasulu Naidu**

Professor, Department of Physiology, Bowring and lady Curzon Medical college and research institute, Bangalore Karnataka.

### ABSTRACT

Polycystic ovary syndrome (PCOS) is a very common reproductive endocrinological disorder seen in women, affecting 5–20% of the reproductive age women globally. Given the pivotal role IR and obesity play in the etiopathogenesis and progression of PCOS and its potential subsequent metabolic and cardiovascular complications, both should be considered essential therapeutic targets. Lifestyle modifications in the treatment of PCOS do not escape criticism and controversy despite being widely accepted recommendations. Physical activity (PA) has been reported to ameliorate anovulation, IR, blood pressure, and lipid profiles in women with PCOS, sometimes independently of weight loss. In addition, novel perspectives into the pathophysiology of PCOS, such as the role of ovarian AGE deposition, suggest avoidance of glycotxin-rich diets as an added recommendation.

**KEYWORDS :** Polycystic Ovary Syndrome, Endocrine And Metabolic Disorders.

### BACKGROUND

Polycystic ovary syndrome (PCOS) is a very common reproductive endocrinological disorder seen in women, affecting 5–20% of the reproductive age women globally [1]. Insulin resistance (IR) and associated metabolic abnormalities appear to play a significant role in the development of PCOS and in sustaining this disorder [2, 3]. A vast majority of the affected women also show hyperinsulinemia, developed as a compensatory physiological body need, which in itself contributes to several problems including overweight. Hyperinsulinemia in these patients contributes to the development of metabolic syndrome, which is a composite of type 2 diabetes, atherosclerosis, obesity and cardiovascular disorders [4, 5]. The primary defect lies at the ovarian level or may be a manifestation of hyperinsulinemia that drives elevated androgen production [6]. Hyperandrogenism in association with ovulatory dysfunction and polycystic ovarian morphology (PCOM) are common features of PCOS, with the ovaries producing large quantities of androgens [1]. This is also accompanied by menstrual disorders (oligo-amenorrhea) [5]. The manifestations of PCOS are not confined to the gynecological sphere; women afflicted by this disease show an increased prevalence of several comorbidities, including obesity, dyslipidemia, hypertension, metabolic syndrome (MS), and type 2 diabetes mellitus (DM2) in comparison with women without PCOS. These features, along with other alterations such as endothelial dysfunction and a chronic low-grade inflammatory state, underlie the greater risk of developing cardiovascular disease and increased all-cause mortality observed in these subjects [7].

### PCOS and endocrine manifestations

In contrast to the characteristic picture of fluctuating hormone levels in the normal cycle, a "steady state" of gonadotropins and sex steroids in women with PCOS is due to the persistent anovulation in which the production of estrogen and androgens are both increased [8, 9]. Anovulatory women with PCOS also have a higher luteinizing hormone (LH) and gonadotropin-releasing hormone (GnRH) pulse frequency and amplitude when compared to the normal midfollicular phase [10]. This enhanced pulsatile secretion of GnRH can be attributed to a reduction in hypothalamic opioid inhibition because of the chronic absence of progesterone [11].

The increased LH secretion, as expressed by the LH: FSH

(follicle-stimulating hormone) ratio, is positively correlated with the increased free estradiol [12]. A sensitive assay for inhibin-B has detected high levels in women with PCO, suggesting that multiple small follicles can suppress FSH by increasing the circulating levels of inhibin-B [13]. However, FSH levels are not totally depressed. Hence new follicular growth is continuously stimulated but not to the point of full maturation and ovulation [14]. Therefore, multiple follicular cysts develop 2–10 mm in diameter, which are theca cells, often luteinized in response to high LH levels.

Hyperthecosis refers to patches of luteinized theca-like cells scattered throughout the ovarian stroma. It is characterized by the same histological findings as seen in polycystic (PCOS) syndrome [15]. The clinical picture of more intense androgenization is a result of greater androgen production. This condition is associated with lower LH levels, which is a possible consequence of the higher testosterone levels blocking estrogen action at the hypothalamic pituitary level. It seems appropriate to view hyperthecosis as a manifestation of the same process of persistent anovulation, but with greater intensity. A greater degree of insulin resistance is correlated with the degree of hyperthecosis [16]. Because, insulin and insulin-like growth factor 1 (IGF-1) stimulate proliferation of thecal interstitial cells, hyperinsulinemia may be an important factor contributing to hyperthecosis [17].

### PCOS and metabolic syndrome

It has been suggested that women with PCOS could reduce their risk of Type 2 diabetes and cardiovascular disease through weight reduction and exercise and that the use of medications that reduce insulin resistance might also be warranted [18]. Some studies have demonstrated the benefits of weight reduction and exercise programs for infertile women with PCOS. There is very little evidence that women with PCOS are at increased risk of cardiovascular disease independent of Type 2 diabetes [19]. This may be due to the action of unopposed estrogen in anovulatory cycles, which might protect women with PCOS, despite the presence of other cardiovascular risk factors. The extent to which Type 2 diabetes contributes to premature morbidity and mortality for women with PCOS remains unclear at present. It is also debated whether it is the PCOS per se or the obesity that is a frequent attribute of the condition or both that is the principal contributor to the observed excess of Type 2 diabetes among women with histologically proven PCOS [20]. An Indian study

which show that dyslipidemia in PCOS is associated with obesity rather than raised testosterone [21]. The results of studies that have considered the relationship between PCOS and lipid levels are inconsistent. The HDL levels are a possible exception as the majority of studies report lower HDL levels among women with PCOS than among controls, regardless of the selection criteria for either cases or controls [22]. Long-term follow-up of women with PCOS treated previously with ovarian wedge resection has shown these women to be at increased risk of developing Type 2 diabetes, independent of obesity [23]. As pregnancy has a diabetogenic effect, all women who are at risk of Type 2 diabetes by virtue of a positive family history of diabetes and/or obesity are also at risk of developing gestational diabetes. Insulin resistance, defined as decreased insulin-mediated glucose utilization, is found in 10-25% when sophisticated dynamic studies of insulin action are performed [24]. However, the criteria for selecting an abnormal cutoff point vary. Insulin resistance in women with PCOS appears to be even more common (up to 50%), both in obese and nonobese women [25]. Reports of the prevalence on insulin resistance in women with PCOS vary depending on the sensitivity and specificity of the tests employed and the heterogeneity of PCOS. Also the criteria of metabolic syndrome itself vary, based on at least three criteria, NCEP [26], WHO [27] and IDF [28] and consequently the prevalence of metabolic syndrome in PCOS would vary depending on the criteria employed.

The association between exposure to unopposed estrogens and an increased risk of endometrial cancer has been well established. Obesity has been shown consistently to be an important risk factor for endometrial cancer. Many studies support the hypothesis that reduced exposure to ovulatory menstrual cycles is protective against breast cancer [29].

## CONCLUSION

Given the pivotal role IR and obesity play in the etiopathogenesis and progression of PCOS and its potential subsequent metabolic and cardiovascular complications, both should be considered essential therapeutic targets [30]. Although traditionally metformin is thought of as a hallmark of PCOS treatment as the mainstay insulin sensitizer, the advent of the distinct phenotypes for this syndrome and the broader acceptance of this categorization bring into question its indication in all cases of PCOS [31]. Uncertainties are even more commonplace surrounding other pharmacologic alternatives habitually considered for PCOS management, such as thiazolidinediones and statins [32, 33].

Lifestyle modifications in the treatment of PCOS do not escape criticism and controversy despite being widely accepted recommendations. Physical activity (PA) has been reported to ameliorate anovulation, IR, blood pressure, and lipid profiles in women with PCOS, sometimes independently of weight loss [34]; yet PA alone does not seem to be able to equal these parameters to non-PCOS subjects [35]. Therefore, it should be accompanied by a complementary diet plan in order to fully potentiate the effects of a lifestyle-modification therapeutic program. Standard weight loss programs may be sufficient for ameliorating features of PCOS, in the form of a nutritionally adequate, fiber-rich, low fat, moderate protein, and high carbohydrate intake diet with a 500–1,000 kcal/day reduction [36]. On the other hand, more specialized low-carbohydrate ketogenic diets have been reported to significantly reduce weight, LH/FSH ratio, testosterone and fasting insulin ratio, and IR in women with PCOS [37], although concerns on their safety on lipid profiles [38] and cardiovascular risk [39] call for careful consideration. Ultimately, a wide range of dietary programs akin to these general concepts are accepted to similarly improve weight, reproductive and metabolic variables in PCOS so long as they boast nutritional adequacy and long term sustainability [40]. In addition, novel perspectives into the pathophysiology of PCOS, such as the

role of ovarian AGE deposition, suggest avoidance of glycotxin-rich diets as an added recommendation [41].

## REFERENCES

- Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowitz B, Teede HJ, Yildiz BO. Polycystic ovary syndrome. *Nat Rev Dis Primers*. 2016;2:16057.
- Amato MC, Vesco R, Vigneri E, Ciresi A, Giordano C. Hyperinsulinism and polycystic ovary syndrome (PCOS): role of insulin clearance. *J Endocrinol Invest*. 2015;38:1319–1326.
- Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. *Endocr Rev*. 2012;33:981–1030.
- Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. *Atherosclerosis*. 2004;173:309–314.
- Polak K, Czyzyk A, Simoncini T, Meczekalski B. New markers of insulin resistance in polycystic ovary syndrome. *J Endocrinol Invest*. 2017;40:1–8.
- Kaufman RP, Baker VM, DiMarino P, Castracane VD. Hyperinsulinemia and circulating dehydroepiandrosterone sulfate in white and Mexican American women with polycystic ovary syndrome. *FertilSteril*. 2006;85:1010–1016.
- Wild RA. Long-term health consequences of PCOS. *Human Reproduction Update*. 2002;8(3):231–241.
- Chang RJ. Ovarian steroid secretion in polycystic ovarian disease. *Semi Reprod Endocrinol* 1984;2:244. Back to cited text no. 3
- Calogero AE, Macchi M, Montanini V, Mongioi A, Maugeri G, Vicari E, et al. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone. *J Clin Endocrinol Metab* 1987;64:980–5.
- Burger CW, Korsen TJ, van Kessel H, van Dop PA, Caron FJ, Schoemaker J. Pulsatile luteinizing hormone patterns in the follicular phase of the menstrual cycle, polycystic ovarian disease (PCOD) and non-PCOD secondary amenorrhea. *J Clin Endocrinol Metab* 1985;61:1126–32.
- Berga SI, Yen SS. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome. *Clin Endocrinol* 1989;30:177–84.
- Lobo RA, Granger L, Goehlsmann U, Mishell DR Jr. Elevations in unbound serum estradiol as a possible mechanism for inappropriate gonadotropin secretion in women with PCO. *J Clin Endocrinol Metab* 1981;52:156–8. Back to cited text no. 7
- Lockwood GM, Muttukrishna S, Groome NP, Mathews DR, Ledger WL. Mid follicular phase pulses of inhibits B are absent in PCOS and are initiated by successful laparoscopic ovarian diathermy: A possible mechanism regulating emergence of the dominant follicle. *J Clin Endocrinol Metab* 1998;83:1730–5. Back to cited text no. 8
- Fausser BC. Observations in favour of normal early follicle development and disturbed dominant follicle selection in polycystic ovary syndrome. *Gynecol Endocrinol* 1994;8:75–82.
- Judd HL, Scully RE, Herbst AL, Yen SS, Ingersol FM, Kleman B. Familial hyperthecosis: Comparison of endocrinologic and histologic findings with PCOD. *Am J ObstetGynecol* 1973;117:979–82. Back to cited text no. 10
- Nagamani M, VamDinh T, Kelver ME. Hyperinsulinemia in hyperthecosis of the ovaries. *Am J ObstetGynecol* 1986;154:384–9. Back to cited text no. 11
- Duleba AJ, Spaczynski RZ, Olive DL. Insulin and insulin like growth factor-I stimulate the proliferation of human ovarian theca-interstitial cells. *FertilSteril* 1998;69:335–40.
- Guzick D. PCOS: Symptomatology, pathophysiology and epidemiology. *Am J ObstetGynaecol* 1998;179:S89–93.
- Maitra A, Pingle RR, Menon PS, Naik V, Gokral JS, Meherji PK. Dyslipidemia with particular regard to apolipoprotein profile in association with polycystic ovary syndrome: A study among Indian women. *Int J Fertil Womens Med* 2001;46:271–7.
- Pierpoint T, Mckeigue PM, Isaacs AJ, Wilt SH, Jacobs HS. Mortality of women with PCOS at long term follow-up. *J Clin Epidemiol* 1998;51:581–6.
- Conway SG, Agarwal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. *Clin Endocrinol* 1992;37:119–25.
- Normal RJ, Hague WM, Masters SC, Wang XJ. Subjects with polycystic ovaries without hyperandrogenaemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome. *Hum Reprod* 1995; 10: 2258–61.
- Dahlgren E, Johansson S, Lindstedt G, Knutsson F, Oden A, Janson PO, et al. Women with PCOS wedge resected in 1956 to 1965: A long-term follow-up focusing on natural history and circulating hormones. *FertilSteril* 1992;57:505–13.
- Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. *J Clin Invest* 1997;100:1166–73.
- Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. *Diabetes* 1989;38:1165–74.
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *J Am Med Assoc* 2001;285:2486–97.
- World Health Organization. Definition, diagnosis and classification of diabetes mellitus. Report of a WHO Consultation. World Health Organization: Geneva; 1999.
- Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome—a new worldwide definition. *Lancet* 2005;366:1059–62.
- Gammon MD, Thompson WD. Polycystic ovaries and the risk of breast cancer. *Am J Epidemiol* 1991;134:818–24.
- Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen

- excess and polycystic ovary syndrome (AE-PCOS) society. *Journal of Clinical Endocrinology and Metabolism*. 2010;95(5):2038–2049.
31. Marshall JC, Dunaif A. Should all women with PCOS be treated for insulin resistance? *Fertility and Sterility*. 2012;97(1):18–22.
  32. Li XJ, Yu YX, Liu CQ, et al. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. *Clinical Endocrinology*. 2011;74(3):332–339.
  33. Hoeger KM. Polycystic ovary syndrome, inflammation, and statins: do we have the right target? *Journal of Clinical Endocrinology and Metabolism*. 2009;94(1):35–37.
  34. Harrison CL, Lombard CB, Moran LJ, Teede HJ. Exercise therapy in polycystic ovary syndrome: a systematic review. *Human Reproduction Update*. 2011;17(2):171–183.
  35. Harrison CL, Stepto NK, Hutchison SK, Teede HJ. The impact of intensified exercise training on insulin resistance and fitness in overweight and obese women with and without polycystic ovary syndrome. *Clinical Endocrinology*. 2012;76(3):351–357.
  36. Poehlman ET, Dvorak RV, DeNino WF, Brochu M, Ades PA. Effects of resistance training and endurance training on insulin sensitivity in nonobese, young women: a controlled randomized trial. *Journal of Clinical Endocrinology and Metabolism*. 2000;85(7):2463–2468.
  37. Mavropoulos JC, Yancy WS, Hepburn J, Westman EC. The effects of a low-carbohydrate, ketogenic diet on the polycystic ovary syndrome: a pilot study. *Nutrition and Metabolism*. 2005;2:35.
  38. Sumithran P, Proietto J. Ketogenic diets for weight loss: a review of their principles, safety and efficacy. *Obesity Research and Clinical Practice*. 2008;2(1):1–13.
  39. Lagiou P, Sandin S, Lof M, Trichopoulos D, Adami HO, Weiderpass E. Low carbohydrate-high protein diet and incidence of cardiovascular diseases in Swedish women: prospective cohort study. *The British Medical Journal*. 2012;344e4026.
  40. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the androgen excess and polycystic ovary syndrome society. *Fertility and Sterility*. 2009;92(6):1966–1982.
  41. Diamanti-Kandarakis E, Bourguignon J, Giudice LC, et al. Endocrine-disrupting chemicals: an endocrine society scientific statement. *Endocrine Reviews*. 2009;30(4):293–342.